Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

FRA:41L Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	49.25	27.19	25.32	124.95	99.04	53.16
Short-Term Investments	-	0.83	0.11	0.09	0.1	0.07
Cash & Short-Term Investments	49.25	28.02	25.44	125.03	99.14	53.23
Cash Growth	180.56%	10.15%	-79.66%	26.13%	86.22%	-21.14%
Accounts Receivable	191.39	114.83	124.55	160.23	129.8	63.34
Other Receivables	0.12	12.61	15.91	21.06	27.83	18.61
Receivables	191.51	127.44	140.46	181.28	157.63	81.95
Inventory	314.79	329.95	337.97	311.94	245.47	227.2
Prepaid Expenses	3.65	2.69	2.73	2.03	1.79	0.01
Other Current Assets	-	1.51	2.74	2.79	2.33	2.18
Total Current Assets	559.19	489.61	509.33	623.07	506.36	364.58
Property, Plant & Equipment	304.63	286.62	253.65	215.54	181.78	155.4
Long-Term Investments	19.11	19.52	0.59	2.2	2.07	1.88
Other Intangible Assets	35.5	28.23	27.74	29.14	31.51	33.93
Long-Term Deferred Tax Assets	3.58	2.26	2.34	2.08	3.85	11.11
Long-Term Deferred Charges	-	5.72	6.16	6.6	7.05	7.49
Other Long-Term Assets	0.07	0.07	0.07	0.07	0.07	0.07
Total Assets	922.07	832.02	799.88	878.7	732.68	574.44
Accounts Payable	102.23	89.93	109.89	125.87	99.4	65.19
Accrued Expenses	-	33.19	28.83	31.67	24.6	23.85
Current Portion of Long-Term Debt	26.31	17.84	8.06	8.27	2.98	2.95
Current Portion of Leases	-	5.85	5.13	4.46	3.44	3.07
Current Income Taxes Payable	22.42	2.38	5.26	-	0.68	-
Current Unearned Revenue	34.47	5.25	39.51	115.39	58.12	25.5
Other Current Liabilities	-	2.21	3.17	8.23	1.17	2.33
Total Current Liabilities	185.42	156.65	199.84	293.89	190.39	122.89
Long-Term Debt	85.12	80.5	38.58	46.04	52.52	53.94
Long-Term Leases	12.2	10.22	13.67	13.4	14.22	14.48
Long-Term Unearned Revenue	5.64	2.75	2.79	3.32	3.79	8.5
Long-Term Deferred Tax Liabilities	0.71	0.37	1.52	0.68	0.78	0.93
Total Liabilities	289.27	250.48	256.39	357.32	261.7	200.74
Common Stock	3.07	3.07	3.24	3.24	3.36	3.36
Additional Paid-In Capital	87.64	87.64	87.64	87.64	87.64	87.64
Retained Earnings	536.06	486.89	556.21	456.7	446.1	302.89
Treasury Stock	-4.98	-5.55	-107.68	-27.56	-66.12	-20.19
Comprehensive Income & Other	-0.05	-0.02	-0.02	-0.01	-0	-0
Total Common Equity	621.74	572.03	539.39	520.01	470.98	373.7
Minority Interest	11.06	9.51	4.11	1.37	-	-
Shareholders' Equity	632.8	581.54	543.49	521.38	470.98	373.7
Total Liabilities & Equity	922.07	832.02	799.88	878.7	732.68	574.44
Total Debt	123.62	114.41	65.43	72.17	73.16	74.44
Net Cash (Debt)	-74.37	-86.39	-39.99	52.87	25.97	-21.21
Net Cash Growth	-	-	-	103.55%	-	-
Net Cash Per Share	-1.45	-1.69	-0.75	0.99	0.47	-0.38
Filing Date Shares Outstanding	51.15	51.15	51.82	53.37	54.85	55.4
Total Common Shares Outstanding	51.15	51.15	51.82	53.37	54.85	55.4
Working Capital	373.77	332.96	309.49	329.19	315.97	241.69
Book Value Per Share	12.16	11.18	10.41	9.74	8.59	6.75
Tangible Book Value	586.24	543.8	511.65	490.87	439.46	339.77
Tangible Book Value Per Share	11.46	10.63	9.87	9.20	8.01	6.13
Land	-	74.8	60.65	45.12	37.25	35.75
Machinery	-	404.19	372.97	303.78	275.44	250.22
Construction In Progress	-	11.01	8.47	40.17	28.06	14.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.